Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging.
Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging.
复制标题
DOI：
10.1016/j.dadm.2015.12.001
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
AIBL Research Group
中科院分区：
文献类型：
--
作者：
Gupta VB;Doecke JD;Hone E;Pedrini S;Laws SM;Thambisetty M;Bush AI;Rowe CC;Villemagne VL;Ames D;Masters CL;Macaulay SL;Rembach A;Rainey-Smith SR;Martins RN;AIBL Research Group
对于阿尔茨海默病（AD）的早期检测，该领域需要可用于以高灵敏度和特异性检测疾病状态的生物标志物。载脂蛋白J（ApoJ，clusterin）通过多种途径参与AD的发病机制。本研究的目的是探讨血浆apoJ作为AD血液生物标志物的潜力。使用澳大利亚成像，生物标志物和生活方式（Aibl）的老化研究，本研究分析了833人的血浆apoJ水平超过基线和18个月。根据临床分类、年龄、性别、载脂蛋白E（APOE）ε4等位基因状态、简易精神状态检查评分、血浆淀粉样蛋白β（Aβ）、新皮质Aβ负荷（通过匹兹堡复合B-正电子发射断层扫描测量）和总校正海马体积分析血浆ApoJ水平。与健康对照组相比，轻度认知障碍（MCI）和AD组的ApoJ均显著升高（HC; P < .0001）。ApoJ与“标准摄取值比率”（SUVR）和海马体积显著相关，与血浆Aβ1-42/Aβ1-40比值弱相关。在基线和18个月时间点，血浆apoJ预测HC的MCI和AD，AD的准确度大于80%，MCI的准确度大于75%。MCI组和AD组的平均apoJ水平均显著较高。ApoJ能够通过APOE ε4等位基因状态区分具有高SUVR的HC和具有低SUVR的HC，这表明它可以被包括在生物标志物组中，以在临床症状发作之前识别AD。
For early detection of Alzheimer's disease (AD), the field needs biomarkers that can be used to detect disease status with high sensitivity and specificity. Apolipoprotein J (ApoJ, also known as clusterin) has long been associated with AD pathogenesis through various pathways. The aim of this study was to investigate the potential of plasma apoJ as a blood biomarker for AD. Using the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, the present study assayed plasma apoJ levels over baseline and 18 months in 833 individuals. Plasma ApoJ levels were analyzed with respect to clinical classification, age, gender, apolipoprotein E (APOE) ε4 allele status, mini-mental state examination score, plasma amyloid beta (Aβ), neocortical Aβ burden (as measured by Pittsburgh compound B-positron emission tomography), and total adjusted hippocampus volume. ApoJ was significantly higher in both mild cognitive impairment (MCI) and AD groups as compared with healthy controls (HC; P < .0001). ApoJ significantly correlated with both “standardized uptake value ratio” (SUVR) and hippocampus volume and weakly correlated with the plasma Aβ1–42/Aβ1–40 ratio. Plasma apoJ predicted both MCI and AD from HC with greater than 80% accuracy for AD and greater than 75% accuracy for MCI at both baseline and 18-month time points. Mean apoJ levels were significantly higher in both MCI and AD groups. ApoJ was able to differentiate between HC with high SUVR and HC with low SUVR via APOE ε4 allele status, indicating that it may be included in a biomarker panel to identify AD before the onset of clinical symptoms.